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Review
Case finding and screening clinical utility of the
Patient Health Questionnaire (PHQ-9 and PHQ-2)
for depression in primary care: a diagnostic meta-
analysis of 40 studies
Alex J. Mitchell, Motahare Yadegarfar, John Gill and Brendon Stubbs
Background
The Patient Health Questionnaire (PHQ) is the most commonly
used measure to screen for depression in primary care but
there is still lack of clarity about its accuracy and optimal
scoring method.
Aims
To determine via meta-analysis the diagnostic accuracy of the
PHQ-9-linear, PHQ-9-algorithm and PHQ-2 questions to detect
major depressive disorder (MDD) among adults.
Method
We systematically searched major electronic databases from
inception until June 2015. Articles were included that reported
the accuracy of PHQ-9 or PHQ-2 questions for diagnosing MDD
in primary care defined according to standard classification
systems. We carried out a meta-analysis, meta-regression,
moderator and sensitivity analysis.
Results
Overall, 26 publications reporting on 40 individual studies were
included representing 26 902 people (median 502, s.d.=693.7)
including 14 760 unique adults of whom 14.3% had MDD. The
methodological quality of the included articles was acceptable.
The meta-analytic area under the receiver operating
characteristic curve of the PHQ-9-linear and the PHQ-2 was
significantly higher than the PHQ-9-algorithm, a difference
that was maintained in head-to-head meta-analysis of studies.
Our best estimates of sensitivity and specificity were 81.3%
(95% CI 71.6–89.3) and 85.3% (95% CI 81.0–89.1), 56.8% (95% CI
41.2–71.8) and 93.3% (95% CI 87.5–97.3) and 89.3% (95% CI
81.5–95.1) and 75.9% (95% CI 70.1–81.3) for the PHQ-9-linear,
PHQ-9-algorithm and PHQ-2 respectively. For case finding
(ruling in a diagnosis), none of the methods were suitable but
for screening (ruling out non-cases), all methods were
encouraging with good clinical utility, although the cut-off
threshold must be carefully chosen.
Conclusions
The PHQ can be used as an initial first step assessment in
primary care and the PHQ-2 is adequate for this purpose
with good acceptability. However, neither the PHQ-2 nor
the PHQ-9 can be used to confirm a clinical diagnosis
(case finding).
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Major depressive disorder (MDD) is a serious, disabling condition
that is often comorbid with other medical presentations.1–4 Most
care for depression is delivered by general practitioners (GPs) and
individually many GPs have considerable experience in managing
depression.5 Approximately 7% of all consultations in primary care
are for depression.6 Yet, clinicians find it challenging to precisely
diagnose depression and often overestimate or underestimate levels
of distress of their patients sometimes resulting in false-positive or
false-negative diagnoses.7 Indeed, GPs are typically able to detect
about half of true cases of depression on a one-off visit1 and once
diagnosed not all patients with depression receive adequate timely
care.8 Although under-detection can lead to inadequate treatment,9
over-detection (misidentification) can lead to inappropriate treat-
ment.9,10 For example, in the Baltimore Epidemiologic Catchment
Area Study, 38% of antidepressant users never met the criteria
for MDD, obsessive–compulsive disorder, panic disorder, social
phobia or generalised anxiety disorder in their lifetime.10 Mitchell
et al1 suggested that this could become a particular problem in
routine care where prevalence rates are modest when false positives
can outnumber false negatives.
Given that many clinicians have highlighted the difficulties in
the timely diagnosis of depression11 and that depression care
is often inadequate,12–14 the use of screening tools in routine
care has been suggested by some as possibly beneficial by
enhancing diagnosis-as-usual. Screening is most usefully defined
as the systematic application of a test to rule out those without a
condition and case finding most usefully defined as the systematic
application of a test to confirm those with a condition.15 Screening
and case finding have been proposed as solutions adopted into
the UK primary care quality outcomes framework (QoF).16 The
use of short screening questionnaires (<5 min) and ultra-short
questionnaires (<2 min) may improve the recognition of depres-
sion if such tests are accurate, acceptable and implemented.17,18 Of
all the possible tools for depression, the depression module of the
Patient Health Questionnaire (PHQ-9) is the most popular current
tool which has three main formats.
1 The PHQ-9 (PHQ-9-linear) scored by simple addition and at a
threshold of 10 or higher had a sensitivity of 88% and a specificity
of 88% for detecting MDD in the initial validation study.19
2 The PHQ-9 (PHQ-9-algorithm) scored by the algorithm
suggested in DSM-IV for MDD (the DSM algorithm method
requires at least five symptoms rated as at least 2 (more than
half the days) (>0 for the suicidal ideation item) plus at least
one of the symptoms scored as at least 2 is either loss of
interest or pleasure or depressed mood all present for 2 weeks
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or more and associated with distress or dysfunction). As this
follows the rules of DSM-IV more precisely, it is anticipated
that this method should be the most accurate.
3 The PHQ-2 is the 2-item version utilising only the first two
questions, namely loss of interest and low mood for the past
2 weeks, scored by simple linear scoring using a threshold of
2 or higher.20
An adaptation of the PHQ-2 also exists where the main
modification is the duration of questioning which is over the past
month rather than 2 weeks. This is known as the Whooley
questions after the original author.
Yet, it is important to acknowledge that the value of screening
and severity assessment has been disputed both in the literature and
in clinical practice. Some authors have stated that routine use of
depression tools should identify patients with either previously
unrecognised MDD or untreated MDD (in effect a demonstration of
added value)21 but policy recommendations and guidelines have been
inconsistent. In 2009, the United States Preventive Services Task Force
(USPSTF) recommended routine depression screening in primary
care settings with follow-up.22 This recommendation has recently
been revised and extended.23 In the UK, the national guidelines have
reversed their advice24 and themost recent draft guidance state there is
little convincing evidence that depression screening will reduce the
number of patients with depression or improve depression symptoms.25
GPs in the UK have been less enthusiastic than patients about
routine use of depression scales,26 leading to the removal of
depression screening incentives from the UK QoF. In 2013, the
Canadian CTFPHC reconsidered its earlier guideline and also
recommended against screening adults for depression in primary
care settings.27 Thus, although some still advocate screening for
depression, others do not and the argument has become polarised.23
Few are putting forth the argument that screening might work in
some circumstances or that further evidence is required from high-
quality studies, leading to observers to suggest that this is a form of
confirmation bias from either side defending an entrenched
position.28
Four previousmeta-analyses have been conducted on the accuracy
of the PHQ-9 but none have specifically been conducted in primary
care.29–32 One previous meta-analysis has been conducted on the
PHQ-2/Whooley questions but is considerably out of date.17 Thus,
the primary objective is to conduct a meta-analysis to determine the
diagnostic accuracy of the PHQ-9-linear, PHQ-9-algorithm and
PHQ-2 questions to detect MDD among adults.
Method
This systematic review was conducted following a predetermined
but unpublished protocol.
Inclusion and exclusion criteria
We included studies that reported the accuracy of PHQ-9/PHQ-2
questions for diagnosing MDD in primary care. The setting had to
be mostly primary care (but not exclusively, containing >50% of
primary care patients) and we identified one study in two
publications with mixed recruitment.33,34 Studies focusing on
one single medical condition in primary care were excluded.35
The studies had to provide sufficient data to allow us to calculate
contingency tables or had to be supplied by authors. We only
included studies that defined MDD according to standard
classification systems such as the ICD or the DSM using a
standardised diagnostic interview schedule (Mini International
Neuropsychiatric Interview (MINI), Structured Clinical Interview
for DSM Disorders (SCID), Composite International Diagnostic
Interview (CIDI), Diagnostic Interview Schedule (DIS) or Revised
Clinical Interview Schedule (CIS-R)).
Information sources and searches
Two independent reviewers searched Embase, Web of Science,
PsycINFO, CINAHL Plus and PubMed from 1998 until June 2015.
We used the key words ‘PHQ’, ‘patient health questionnaire’,
‘screening’, ‘depression’, ‘MDD’, ‘primary care’ and ‘general
practice’.
Data abstraction
We collected information about study characteristics and quality
using a standardised data collection form. We included the
following characteristics: setting, country, age of sample, gender
of sample, year of study, sample size, masking of the assessor of
the reference test, data integrity, cut-off score and translation of
non-English versions of PHQ-9. When an article appeared to meet
the criteria but did not contain sufficient data, we contacted the
authors up to two times a month.
Study selection
After the removal of duplicates, two independent reviewers
screened the titles and abstracts of all potentially eligible articles.
Both authors applied the eligibility criteria, and a list of full text
articles was developed through consensus. The two reviewers then
considered the full texts of these articles and the final list of
included articles was reached through consensus. A third reviewer
was available for mediation throughout this process.
Methodological quality assessment
We used the Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) tool to assess risk of bias factors in primary studies,
and these factors will be included as study-level variables in
analyses.36 The updated QUADAS-2 guidelines stipulate that it
should be adapted for each specific review. We employed the
QUADAS-2 adaptation utilised in a recent generic PHQ meta-
analysis.30 The QUADAS-2 incorporates assessments of risk of
bias across four core domains: patient selection, the index test,
the reference standard and the flow and timing of assessments.
Two reviewers independently assessed risk of bias with any
discrepancies resolved by consensus. Two reviewers also indepen-
dently assessed outliers that may be qualitatively different in
study design.
Meta-analysis and proposed subgroup analysis
A pooled meta-analysis of suitable studies was conducted to
identify overall test accuracy, sensitivity, specificity, combined
Youden score, positive and negative predictive values (PPV/NPV),
positive and negative likelihood ratios (LR+/LR−) and positive
and negative clinical utility index (CUI+/CUI−). Further details
are available at www.clinicalutility.co.uk. The CUI is a proxy for
the applied value of a test with a qualitative as well as quantitative
interpretation.37–39 Clinical utility may be more important to
clinicians than validity.40 Clinical utility estimates the clinical
value of a diagnostic test taking into account both the accuracy of
the test and its occurrence. The positive utility index (for rule-in
or case-finding accuracy) is a product of sensitivity and PPV and
the negative utility index (for rule-out or screening accuracy) is a
product of Sp x NPV. The interpretation of the CUI is 0.93–1.00
near perfect value, 0.81–0.92 excellent, 0.64–0.80 good, 0.49–0.63
fair, 0.36–0.48 poor and <0.36 very poor.
Sensitivity and specificity are generally regarded as intrinsic char‐
acteristics of a test and independent of prevalence and are a useful
initial metric, but these measures do not reflect clinical practice or
inform clinicians how to interpret a positive or negative test.41
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Summary measures of diagnostic accuracy typically use receiver
operating characteristic (ROC) curve analysis, by which sensitivity
and specificity linked with all possible cut-off scores were calculated
and plotted.42 For an individual study, an optimal cut-off score
is chosen which balances sensitivity and specificity. ROC curve
data are a proportion with a confidence interval which can
be combined across all qualifying studies. From the supplied data,
we constructed 2 × 2 tables for each cut-off score and computed any
missing values. For completeness, we also performed a bivariate
meta-analysis to obtain pooled estimates of specificity and sensitiv-
ity and their associated 95% confidence intervals (CIs). We
constructed summary ROC curves using the bivariate model to
produce a 95% confidence ellipse within the ROC curve space.
Each data score in this space represents a separate study. We also
constructed a Bayesian plot of conditional probabilities which
shows all PPVs and NPVs across every possible prevalence.
We assessed between-study heterogeneity using the I2
statistic43 which describes the percentage of total variation
across studies that is caused by heterogeneity rather than chance.
As per convention, we considered an I2 value of 25% to be
low, 50% to be moderate and 75% to be high. We explored the
causes of heterogeneity if there was significant between-study
heterogeneity. Publication bias was assessed by Harbord or
Egger methods.44
For a secondary moderator analysis, we performed sub-
analysis in clinically relevant subgroups such as those studies
with a head-to-head comparison of tools in the same sample. We
also attempted a logistic meta-regression analysis of diagnostic
accuracy using the 50th percentile of Youden score (sum of
sensitivity and specificity) using covariates in the meta-regression
model.45 We investigated heterogeneity resulting from the char-
acteristics of the sample or study design by exploring the effects of
potential predictive variables.
Results
Search results
The initial search yielded 777 hits. After removal of duplicates,
621 abstracts and titles were screened (Fig. 1). At the full-text
review stage, 58 articles were considered and 32 were subsequently
excluded, leaving 26 publications and 40 different analyses that
were included in the review.19,32,33,46–68 Details regarding the
search results, including reasons for exclusion of articles are
summarised in Fig. 1.
Records excluded 
(n=444)
Records screened 
(n=502)
Additional records identified 
through other sources
(n=1)Identification
Eligibility
Included
Screening
Records identified through 
database searching 
(n=777)
Studies included in meta-
analysis 
(n=26)
Full-text articles excluded with 
reasons:
n=28 no primary care
n=2 no gold standard
n=2 specialist population
Records after duplicates removed 
(n=621)
Full-text articles assessed 
for eligibility 
(n=58)
Fig. 1 PRISMA ﬂow diagram of search strategy.
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Case-finding and screening clinical utility of the PHQ-9 and PHQ-2
Study and participant characteristics
Details of the included studies are summarised in Table 1. Briefly,
11 studies examined the PHQ-9, 9 examined the PHQ-9-algoithm
and 20 examined the PHQ-9-linear. Several studies compared
diagnostic methods within the same population, allowing a head-
to-head comparison. Of particular interest, Thompson &
Higgens,45 Manea et al32 and Lowe et al33 compared all three
diagnostic methods. Chen et al, Kroenke et al, Liu et al, de Lima
Osório et al, 2009, Phelan et al and Richardson et al compared the
PHQ-2 with the PHQ-9-linear.19,50,52,57,60,61 Lamers et al, Lotrakul
et al, Wittkampf et al and Zuithoff et al compared the PHQ-9-
algorithm with the PHQ-9-linear. In these head-to-head studies,
the cut-off thresholds were consistent, namely PHQ-2 (linear) ≥2
and PHQ-9 (linear) ≥10.56,58,66,68
The total sample size was 26 902 (median 502, s.d.=693.7)
with a mean patient age of 49.38 years, and 61% were female.
There were 23 706 individuals without depression according to the
criterion reference and 3009 with depression, meaning that the
prevalence of depression in primary care was 11.3% (95% CI
10.92–11.68%) from simple pooling of data. However, as several
publications used multiple tests, after limiting the analysis to
unique adults, there were 14 760 people, of whom 2117 had
depression (14.3%; 95% CI 11.3–17.7).
Methodological quality
Supplementary Table DS1 summarises the QUADAS-2 scores for
all of the included studies. Only four studies were judged low risk
of bias across all four domains.33,45,55,59 Three studies had either
high risk of bias or were considered possible outliers. Richardson
et al,61 utilised adolescents seen in primary care; Whooley et al,65
used the Whooley questions and was eventually excluded; finally
Cannon et al,48 used lifetime risk of depression rather than
current depression (although this did not significantly influence
the recorded prevalence levels). We used this information as a
moderator analysis.
Diagnostic accuracy of the PHQ
Sensitivity and specificity meta-analysis
Main analysis. The diagnostic validity meta-analysis gave over-
all sensitivity estimates of 82.2% (95% CI 74.3–88.9), 58.4% (95%
CI 44.5–71.7) and 89.9% (95% CI 83.4–94.9) for the PHQ-9-
linear, PHQ-9-algorithm and PHQ-2 respectively. In all cases,
there was significant heterogeneity but no significant publication
Table 1 Summary of included studies
Author PHQ method Sample mean age and
% male/female
Sample
size
Prevalence of
depression, %
Reference standard
Lowe et al34 PHQ-2 (linear) ≥2 42 years, 32.5% male 520 13.7 SCID, DSM-IV
Löwe et al33 PHQ-9-linear and algorithm 41.7 years, 32.9% male 501 13.2 SCID, DSM-IV
Arroll et al46 PHQ-2 (linear) ≥2; PHQ-9
(linear) ≥10; PHQ-9
(algorithm)
49 years, 39% male 2642 6.2 CIDI, DSM-IV
Ayalon et al47 PHQ-9 (algorithm) 75 years 59.5% male 153 3.9 SCID, DSM-IV
Azah et al48 PHQ-9 (linear) ≥10 38.7 years, 38.3% male 180 46.1 CIDI, ICD-10
Cannon et al49 PHQ-9 (algorithm) 57.2 years, 54% male 526 26.6 SCID DSM-IV MDD lifetime
Chen et al50 PHQ-9 (linear) ≥10 Age not reported, 47% male 262 16.7 SCID, DSM-IV
Chen et al51 PHQ-2 (linear) ≥2; PHQ-9
(linear) ≥10
68.5 years, 56.3% female 77 54.5 SCID DSM-IV
De Lima Osório
et al52
PHQ-9 (linear) ≥10; PHQ-2
(linear) ≥2
48% under 30, 52% between
31 and 50 years, 100%
female
177 33.9 SCID DSM-IV
Gelaye et al53 PHQ-9 (linear) ≥10 35.1 years, 61.3% female 363 12.7 SCAN DSM-IV
Gilbody et al54 PHQ-9 (linear) ≥10 42.5 years, 77.1% female 96 37.5 SCID DSM-IV
Henkel et al55 PHQ-2 (linear) ≥2 53.9 years, 75% female 382 10.0 SCID DSM
Kroenke et al19 PHQ-9 (linear) ≥10 46 years, 66% female 580 7.1 DSMIIR
Lamers et al56 PHQ-9 (algorithm); PHQ-9
(linear) ≥8
71.4 years, 51.8% male 713 17.3 MINI DSM-IV
Liu et al57 PHQ-2 (linear) ≥2; PHQ-9
(linear) ≥10
18 years or older, 39% male 1532 3.3 SCAN DSM-IV
Lotrakul et al58 PHQ-9 (linear) ≥10; PHQ-9
(algorithm)
45 years, 73.7% female 279 6.8 MINI DSM-IV
Patel et al59 PHQ-9 (linear) ≥10 37.5 years, 56.4% female 598 5.5 ICD-10
Phelan et al60 PHQ-2 (linear) ≥2; PHQ-9
(linear) ≥10
78 years, 62% female 69 11.6 SCID DSM
Richardson et al61 PHQ-2 (linear) ≥2; PHQ-9
(linear) ≥10
15.3 years, 60% female 442 4.3 DIS for MDD in children (DISC)
Sherina et al62 PHQ-9 (linear) ≥10 30.9 years, 100% female 146 12.1 CIDI, ICD-10
Spitzer et al63 PHQ-9 (algorithm) 46 years, 66% female 585 10.0 DSM
Sung et al64 PHQ-9 >6 36.1 years, 65.3% female 400 3.0 MINI DSM
Wittkampf et al66 PHQ-9 (linear) ≥10; PHQ-9
(algorithm)
49.8 years, 66.7% female 664 12.3 SCID-I
Yeung et al67 PHQ-9 (linear) ≥15 Not reported 184 22.8 SCID DSM
Zuithoff et al68 PHQ-2 (linear) ≥2; PHQ-9
(linear) ≥10; PHQ-9
(algorithm)
51 years, 37% female 1352 13.0 CIDI DSM-IV
CIDI, Composite International Diagnostic Interview; DIS, Diagnostic Interview Schedule; DISC, Diagnostic Interview Schedule for Children; DSM, Diagnostic and Statistical Manual of Mental
Disorders; ICD, International Classification of Diseases; MDD, major depressive disorder; MINI, Mini International Neuropsychiatric Interview; PHQ, Patient Health Questionnaire; SCAN,
Schedules for Clinical Assessment in Neuropsychiatry; SCID, Structured Clinical Interview for DSM Disorders.
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bias (see Table 2 which contains the heterogeneity and publica-
tion bias data for all of the pooled analysis). The pooled specificity
was 84.7% (95% CI 80.4–88.5), 92.1% (95% CI 85.9–96.6) and
72.6% (95% CI 66.0–78.7) for the PHQ-9-linear, PHQ-9-algo-
rithm and PHQ-2 respectively. In the sensitivity analysis (in
which we removed the three outliers) and in the bivariate
analysis, the results were broadly unchanged (Table 3 and Fig.
2) but they did generate our best estimate of sensitivity of 81.3%
(95% CI 71.6–89.3) and specificity of 85.3% (95% CI 81.0–89.1)
for the PHQ-9-linear; a best estimate of sensitivity of 89.3% (95%
CI 81.5–95.1) and specificity of 75.9% (95% CI 70.1–81.3) for the
PHQ-2; a best estimate of sensitivity of 56.8% (95% CI 41.2–71.8)
and specificity of 93.3% (95% CI 87.5–97.3) for the PHQ-9-
algorithm.
Subanalysis (head to head) PHQ-9-linear v. PHQ-2. In a sub‐
analysis restricted to head-to-head studies on the same population,
the sensitivity of the PHQ-9-linear was 87.0% (95% CI 75.81–
95.07) v. 91.4% (95% CI 83.60–96.92) for the PHQ-2. The
specificity of the PHQ-9-linear was 87.17 (95% CI 81.10–92.20)
v. 72.23% (95% CI 63.96–79.81) for the PHQ-2. In the sensitivity
analysis, the results were unchanged (Table 3).
Subanalysis (head to head) PHQ-9-linear v. PHQ-9-algorithm. In
a subanalysis restricted to head-to-head studies on the same
population, the sensitivity of the PHQ-9-linear was 81.1% (95% CI
63.34–93.86) v. 53.1% (95% CI 36.44–69.31) for the PHQ-9-
algorithm. The specificity of the PHQ-9-linear was 86.34% (95%
CI 80.36–91.38) v. 95.71% (95% CI 93.54–97.45) for the PHQ-9-
algorithm, suggesting significantly lower specificity for the PHQ-9-
linear. However, caution is necessary as these results are from a
predefined cut-point of >10. Results were broadly unchanged in the
sensitivity analyses (Table 3).
Cut-off analysis: effect of cut-off thresholds. In an analysis
restricted to specific cut-offs, we analysed the effect of choosing
different fixed cut-off thresholds on the PHQ-2 and PHQ-9 when
scored using linear scoring. Results are shown in Table 3. Inevitably, as
the cut-point increased sensitivity reduced and specificity increased.
For the PHQ-9, looking at combined sensitivity and specificity
(Youden index), the optimal cut-off would be ≥10 followed by ≥11.
Table 2 Inconsistency and bias analysis in Patient Health Questionnaire (PHQ) data in primary care
Test Sensitivity bias, % (95% CI) Specificity bias, % (95% CI) ROC bias, % (95% CI)
Main results
PHQ-9-linear
n=20
I2 (inconsistency) = 90.4
(87 to 92.5)
Harbord: bias = 3.08
(92.5% CI −0.604 to 6.77) P=0.1314
I2 (inconsistency) = 96.6 (96 to 97.1)
Harbord: bias = −5.742 (92.5% CI −10.38
to –1.097) P=0.0312
I2 (inconsistency) = 77.2
56.8 to 85.6)
Egger: bias = −0.805 (−2.50 to
0.89) P=0.3154
PHQ-9-algorithm
n=9
I2 (inconsistency) = 94.8
(92.7 to 96.1)
Harbord: bias = 0.363
(92.5% CI −7.707 to 8.433)
P=0.9277
I2 (inconsistency) = 98.3 (97.9 to 98.5)
Harbord: bias = −13.19 (92.5% CI
−31.689 to 5.302) P=0.1797
I2 (inconsistency) = 92.1 (87.8 to
94.4)
Egger: bias = 1.33 (−7.685 to
10.345) P=0.7375
PHQ-2
n=11
I2 (inconsistency) = 85.3
(74.9 to 90.2)
Harbord: bias = 0.98
(92.5% CI −2.846 to 4.815)
P=0.6175
I2 (inconsistency) = 97 (96.2 to 97.5)
Harbord: bias = −3.89 (92.5% CI −11.382
to 3.593) P=0.3225
I2 (inconsistency) = 73.2 (14 to 86.4)
Egger: bias = −0.64 (−6.848 to
5.554) P=0.7865
Head-to-head results
PHQ-9-linear
n=8
I2 (inconsistency) = 88.5 (79.4 to 92.5)
Harbord: bias = 1.22693 (92.5% CI
−4.335 to 6.789) P=0.6519
I2 (inconsistency) = 96.7 (95.6 to 97.4%)
Harbord: bias = −4.17 (92.5% CI −12.913
to 4.558) P=0.3433
I2 (inconsistency) = 86.2 (57.6 to
92.8)
Egger: bias = −1.03 (−11.014 to
8.950) P=0.6999
PHQ-2-linear
n=8
I2 (inconsistency) = 83.2 (65.5 to 89.8)
Harbord: bias = −0.18 (92.5% CI −4.559
to 4.198) P=0.9321
I2 (inconsistency) = 97.1 (96.2 to 97.7)
Harbord: bias = −4.01 (92.5% CI −12.868
to 4.830) P=0.3664
I2 (inconsistency) = 17.7 (0 to 73.2)
Egger: bias = −1.93 (−4.395 to
0.526) P=0.0774
PHQ-9-algorithm
n=6
I2 (inconsistency) = 94.2 (90.5 to 96)
Harbord: bias = 6.96 (92.5% CI −4.920
to 18.852) P=0.2336
I2 (inconsistency) = 91.2 (83.7 to 94.3)
Harbord: bias = −5.02 (92.5% CI −15.119
to 5.069) P=0.2996
I2 (inconsistency) = 92.4 (83.6 to
95.5)
Egger: bias = 3.27 (−25.876 to
32.416) P=0.6769
Moderator analysis
PHQ-2
n=9
Higher quality;
same cut-off;
adults
I2 (inconsistency) = 87.1 (77.1 to 91.5)
Harbord: bias = 1.22 (92.5% CI −3.194
to 5.641) P=0.5809
I2 (inconsistency) = 95.8 (94.2 to 96.7)
Harbord: bias = −1.86 (92.5% CI −9.244
to 5.506) P=0.6128
I2 (inconsistency) = 76.3 (0 to 89.4)
Egger: bias = −0.44 (−13.793 to
12.893) P=0.8979
PHQ-9-linear
n=16
Higher quality;
same cut-off;
adults
I2 (inconsistency) = 92.1 (89.3 to 93.9)
Harbord: bias = 3.46 (92.5% CI –1.240
to 8.162) P=0.1786
I2 (inconsistency) = 95.9% (94.9 to 96.6)
Harbord: bias = −5.86 (92.5% CI −10.423
to 1.313) P=0.0266
I2 (inconsistency) = 80.8 (61.1 to
88.3)
Egger: bias = −3.20 (−6.581 to
0.173) P=0.0598
PHQ-9-algorithm
n=8
Higher quality;
same cut-off;
adults
I2 (inconsistency) = 95.1 (93 to 96.4)
Harbord: bias = 0.35 (92.5% CI −8.228
to 8.942) P=0.9316
I2 (inconsistency) = 98.1 (97.6 to 98.4)
Harbord: bias = −12.03 (92.5% CI
−33.868 to 9.808) P=0.2808
I2 (inconsistency) = 93 (89.1 to 95)
Egger: bias = 1.41 (−8.589 to
11.426) P=0.7406
ROC, receiver operating characteristic.
Values in bold are significant.
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Table 3 Summary of Patient Health Questionnaire (PHQ) analysis in primary care
Test Sensitivity, % (95% CI) Specificity, % (95% CI) PPV NPV ROC CUI+ CUI- LR+ LR-
Main results
PHQ-9-linear n=20 82.2 (74.3–88.9) 84.7 (0.80–0.89) 38.0%
(36.1–
39.9%)
97.7%
(97.3–
98.0%)
0.910
(0.892–
0.930)
0.312 (0.311–0.313)
‘very poor’
0.827 (0.826–
0.828)
‘excellent’
5.37
(5.09–
5.67)
0.21
(0.19–
0.24)
PHQ-9-algorithm n=9 58.4 (44.5–71.7) 92.1 (85.9–96.6) 47.4%
(44.7–
50.1%)
94.8%
(94.3–
95.3%)
0.733
(0.676–
0.795)
0.277 (0.276–0.278)
‘very poor’
0.873 (0.873–
0.873)
‘excellent’
7.39
(6.77–
8.07)
0.45
(0.42–
0.49)
PHQ-2 n=11 89.9 (83.4–94.9) 72.6 (66.0–78.7) 23.1%
(21.5–
24.7%)
97.5%
(97.0–
97.9%)
0.860
(0.819–
0.903)
0.188 (0.187–0.189)
‘very poor’
0.708 (0.707–
0.709 ‘good’
2.97
(2.82–
3.12)
0.26
(0.22–
0.30)
Head-to-head results
PHQ-9-linear n=8 87.0 (75.8–95.1) 87.2 (81.1–92.2) 38.2%
(35.1–
41.2%)
98.6%
(98.3–
98.9%)
0.920
(0.915–
0.924)
0.322 (0.321–
0.323)‘very
poor’
0.877 (0.987–
0.878)
‘excellent’
7.66
(7.04–
8.33)
0.18
(0.14–
0.22)
PHQ-2-linear n=8 91.5 (83.6–96.9) 72.2 (64.0–79.8) 22.7%
(20.8–
24.6%)
99.0%
(98.7–
99.3%)
0.900
(0.865–
0.934)
0.205 (0.205–0.206)
‘very poor’
0.742 (0.741–
0.743 ‘good’
3.61
(3.42–
3.81)
0.13
(0.10–
0.17)
PHQ-9-algo n=6 53.0 (36.4–69.3) 95.7 (93.5–97.5) 58.4%
(54.1–
62.8%)
94.1%
(93.5–
94.7%)
0.715
(0.628–
0.815)
0.273 (0.272–0.275)
‘very poor’
0.905 (0.904–
0.906)
‘excellent’
12.35
(10.56–
14.45)
0.55
(0.51–
0.50)
Moderator analysis
PHQ-9-linear n=16 Higher quality;
same cut-off; adults
81.3 (71.6–89.3)
82.33(72.0–89.4)a
85.3 (81.0–89.1) 86.4
(81.2–90.4)a
44.2%
(41.9–
46.6%)
38.9
(36.8–
41.0)
97.5
(97.2–
97.9)
0.316 (0.315–0.317)
‘very poor’
0.832 (0.832–
0.832)
‘excellent’
5.53
(5.21–
5.87)
0.22
(0.19–
0.25)
PHQ-9-algorithm n=8 Higher
quality; same cut-off; adults
56.8 (41.2–71.8) 54.0
(40.0–67.5)a
93.3 (87.5–97.3) 95.9
(94.0 – 97.3)a
60.3%
(57.0–
63.6%)
48.3%
(45.4–
51.3)
95.1%
(94.7–
95.6)
0.275 (0.274–0.276)
‘very poor’
0.887 (0.887–
0.887)
‘excellent’
8.46 (97.67
–9.33)
0.46
(0.43–
0.50
PHQ-2 n=9 Higher quality;
same cut-off; adults
89.3 (81.5–95.1) 91.4
(81.9–96.2)a
75.9% (70.1–81.3)
76.3 (69.6–82.0)a
27.7%
(25.8–
29.6%)
26.5%
(24.6–
28.3%)
98.6%
(98.3–
99.0%)
0.236 (0.235–0.237)
‘very poor’
0.749 (0.749–
0.749) ‘good’
3.71
(3.52–
3.90
0.14
(0.11–
0.18)
PPV, positive predictive value; NPV, negative predictive value; ROC, receiver operating characteristic; CUI+, positive clinical utility index; CUI−, negative clinical utility index; LI+, positive likelihood ratio; LI−, negative likelihood ratio.
a. Alternative calculation based on bivariate calculation in STATA.
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Moderator analysis: effect of influencing variables. In a
moderator analysis we found no association between country,
mean age, gender, year of publication or sample size.
ROC curve meta-analysis
Main analysis PHQ-9 linear, PHQ algorithm and PHQ-2. The
pooled ROC diagnostic validity meta-analysis gave an overall
area estimate of 0.91 (95% CI 0.892–0.930) for the PHQ-9-
linear, 0.733 (95% CI 0.676–0.795) for the PHQ-9-algorithm
and 0.860 (95% CI 0.819–0.903) for the PHQ-2. In all cases
there was significant heterogeneity but no significant publication
bias; see Table 3 (summary of results). Results were broadly
unchanged in moderator analysis with area under the ROC of
0.910 (95% CI 0.882–0.939) for the PHQ-9 linear, 0.732 (0.667–
0.803) for the PHQ-9-algorithm and 0.877 (0.824–0.934) for the
PHQ-2.
Subanalysis (head to head) PHQ-9-linear v. PHQ-2. The area
under the ROC for the PHQ-2 was 0.898 (95% CI 0.864–0.933)
and 0.922 (95% CI 0.882–0.964) for the PHQ-9-linear in the
head-to-head studies. Once again, results were unchanged in the
sensitivity analysis.
Subanalysis (head to head) PHQ-9-linear v. PHQ-9-algorithm.
The area under the ROC for the PHQ-9-linear was 92.01 (95% CI
91.53–92.48) and 71.49 (95% CI 62.75–81.45) for the PHQ-9-
algorithm when restricted to four head-to-head studies.
Subanalysis (head to head) PHQ-2 v. PHQ-9-algorithm. There
were insufficient data for this comparison.
Test performance: case finding v. screening
Examining PPV, the diagnostic validity meta-analysis suggested
superior PPV of the PHQ-9-algorithm 47.4% (95% CI 44.7–50.1)
compared with the PHQ-2 23.1% (95% CI 21.5–24.7); however,
caution is required because prevalence is not controlled for (i.e.
not matched in both analyses) (correction for prevalence is shown
in the Bayesian curve of conditional probabilities). Examining
NPV, meta-analysis suggested superior PPV of the PHQ-2 97.5%
(95% CI 97.0–97.9) compared with the PHQ-9-algorithm 94.8%
(95% CI 94.3–95.3); however, caution is again required because
prevalence is not controlled for in this analysis. Results using
likelihood ratios are shown in Table 3 but more informative is the
clinical utility. For case finding (CUI+), all methods were dis‐
appointing, with the following results: PHQ-9-linear 0.312 (95%
CI 0.311–0.313), PHQ-9-algorithm 0.277 (95% CI 0.276–0.278)
and PHQ-2 0.188 (95% CI 0.187–0.189), all suggesting very poor
performance at typical prevalence rates seen in primary care.
Results were not substantially different using a moderator analysis
for high-quality studies with a fixed cut-off or using head-to-head
analysis.
For application as a screening test (CUI+) all methods were
satisfactory with the following results: PHQ-9-linear 0.827 (95%
CI 0.826–0.828), PHQ-9-algorithm 0.873 (95% CI 0.873–0.873)
and PHQ-2 0.708 (95% CI 0.707–0.709), all suggesting good to
excellent performance at typical prevalence rates seen in primary
care. Results were not substantially different using a moderator
analysis for high-quality studies with a fixed cut-off or using head-
to-head analysis. All analyses suggested the optimal rule-out
screening test would be the PHQ-9-algorithm, closely followed
by the PHQ linear.
Using a Bayesian curve of conditional probabilities, the
performance of each test (judged by PPV and NPV) can be
demonstrated at every possible prevalence applicable to different
settings (Figs. 3 and 4). From the Bayesian curve, the most
encouraging test would be the PHQ-2 used as an initial screener
followed by either the PHQ-9-linear or another suitable case-
finding tool.
Cut-off analysis: effect of cut-off thresholds
On the PHQ-9, looking at combined PPV and NPV (predictive
summary index), the optimal cut-point would be ≥14. For the
PHQ-2, looking at combined sensitivity and specificity (Youden
index), the optimal cut-off would be ≥3 closely followed by ≥2
(note that ≥2 is the conventional threshold). However, looking at
combined PPV and NPV (predictive summary index), the optimal
cut-point would be ≥6, followed by the ≥5. Comparing the PHQ-
9 and the PHQ-2 across all possible cut-offs shows that neither is
satisfactory as a case-finding tool in primary care at any cut-off,
but the optimal single method is the PHQ-2 at a threshold of ≥6.
Six per cent of those without MDD have a score of 5 or lower on
the PHQ-2 and of those with a score of 5 or lower, 93.5% are true
negatives (true non-cases) (Tables 2–4).
Discussion
A previous meta-analysis of 41 studies involving 50 371 indivi-
duals in primary care found a pooled prevalence of 18.4% (95% CI
13.5–23.9) in adults aged 18–65 years using semi-structured
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Table 4 PHQ cut-off threshold analysis in primary care
Test Sensitivity, % (95% CI) Specificity, % (95% CI) PPV NPV CUI+ CUI− LR+ LR−
PHQ-2
Cut PHQ-2 ≥1
n=20
96.05 (92.29–98.60) 52.18 (43.42–60.8) 14.7 (13.6–15.9) 99.4 (99.1–99.6) 0.141 (0.140–0.142)
‘very poor’
0.519 (0.519–0.519)
‘fair’
2.01 (1.95–2.07) 0.07 (0.05–0.11)
Cut PHQ-2 ≥2
n=9
92.20 (85.21–97.10) 70.98 (64.63–76.94) 22.8 (21.2–24.5) 99.0 (98.7–99.3) 0.211 (0.210–0.212)
‘very poor’
0.703 (0.703–.703)
‘good’
3.18 (3.04–3.32) 0.11 (0.08–0.14)
Cut PHQ-2 ≥3
n=11
76.22 (61.1–88.53) 88.66 (85.01–91.86) 38.6 (35.9–41.3) 97.6 (97.2–97.9) 0.294 (0.293–0.295)
‘very poor’
0.865 (0.865–0.865)
‘excellent’
6.74 (6.23–7.30) 0.27 (0.23–0.31)
Cut PHQ-2 ≥4
n=11
61.46 (44.00–77.52) 94.14 (91.73–96.15) 53.4 (49.7–57.2) 95.7 (95.2–96.3) 0.329 (0.328–0.330
‘very poor’
0.901 (0.901–0.901)
‘excellent’
10.45 (9.22–11.85) 0.41 (0.37–0.45)
Cut PHQ-2 ≥5
n=11
47.33 (26.78–68.37) 97.60 (95.36–99.12) 72.8 (67.2–78.4) 93.2 (92.2–94.1) 0.344 (0.241–0.346)
‘very poor’
0.909 (0.908–0.910)
‘excellent’
19.77 (15.23–25.68) 0.54 (0.49–0.60)
Cut PHQ-2 ≥6
n=11
51.80 (23.07–79.88) 98.63 (96.91–99.66) 83.3 (78.5–88.2) 93.5 (92.6–94.4) 0.421 (0.419–0.424)
‘poor’
0.421 (0.419–0.424)b
‘poor’
0.922 (0.921–0.923)a
‘excellent’
0.50 (0.45–0.56)
PHQ-9
Cut PHQ-9 ≥6
n=20
89.81 (81.91–95.63) 62.79 (51.02–73.84) 28.9 (26.7–31.1) 97.3 (96.6–98.0) 0.259 (0.258–0.250)
‘very poor’
0.611 (0.611–0.611)
‘fair’
2.41 (2.28–2.55) 0.16 (0.13–0.21)
Cut PHQ-9 ≥7
n=20
84.69 (74.32–92.75) 69.17 (57.72–79.53) 31.6 (29.2–34.1) 96.4 (95.6–97.2) 0.268 (0.267–0.269)
‘very poor’
0.667 (0.666–0.668)
‘good’
2.75 (2.57–2.93) 0.22 (0.18–0.27)
Cut PHQ-9 ≥8
n=20
80.25 (71.00–88.09) 76.54 (69.59–82.84) 29.4 (27.4–31.5) 96.9 (96.4–97.5) 0.236 (0.235–0.237)
‘very poor’
0.742 (0.71–0.743)
‘good’
3.41 (3.21–3.63) 0.26 (0.22–0.30)
Cut PHQ-9 ≥9
n=20
81.31 (69.69–90.64) 79.82 (72.51–86.26) 32.3 (30.0–34.7) 97.3 (96.8–97.8) 0.263 (0.262–0.264)
‘very poor’
0.777 (0.776–0.778)
‘good’
4.03 (3.77–4.31) 0.23 (0.20–0.28)
Cut PHQ-9 ≥10
n=20
81.3 (71.6–89.3) 85.3 (81.0–89.1) 44.2 (41.9–46.6) 97.0 (96.7–97.4) 0.333 (0.337–0.339)
‘very poor’
0.863 (0.863–0.863)
‘excellent’
6.90 (6.44–7.40) 0.27 (0.24–0.30)
Cut PHQ-9 ≥11
n=20
75.40 (60.77–87.52) 87.86 (82.77–92.17) 44.6 (41.8–47.4) 96.5 (96.0–97.0) 0.336 (0.335–0.337)
‘very poor’
0.848 (0.848–0;.848)
‘excellent’
6.23 (5.74–6.76) 0.28 (0.25–0.32)
Cut PHQ-9 ≥12
n=20
68.37 (54.71–80.58) 90.88 (87.54–93.73) 49.1 (46.1–52.0) 95.7 (95.2–96.2) 0.336 (0.335–0.336)
‘very poor’
0.870 (0.870–8.70)
‘excellent’
7.51 (6.85–8.23) 0.35 (0.31–0.39)
Cut PHQ-9 ≥13
n=20
69.92 (58.39–80.30) 92.93 (89.33–95.83) 60.2 (55.5–64.9) 95.3 (94.4–96.1) 0.421 (0.419–0.423)
‘poor’
0.421 (0.419–0.423)b
‘poor’
9.84 (8.38–11.55) 0.32 (0.28–0.38)
Cut PHQ-9 ≥14
n=20
56.04 (42.88–68.77) 96.57 (94.48–98.18) 73.4 (67.1–79.8) 92.9 (91.6–94.2) 0.411 (0.408–0.415)
‘poor’
0.898 (0.897–0.898)a
‘excellent’
16.5 (12.26–22.21) 0.46 (0.40–0.53)
PPV, positive predictive value; NPV, negative predictive value; ROC, receiver operating characteristic; CUI+, positive clinical utility index; CUI–, negative clinical utility index; LI+, positive likelihood ratio; LI–, negative likelihood ratio.
a. Optimal cut-off for ruling out those without depression (screening).
b. Optimal cut-off for ruling in those with depression (case-finding).
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interviews.1 In this study, we found a slightly lower prevalence of
depression in primary care of 14.3% (95% CI 11.3–17.7%) across
14 760 adults. The PHQ-9-linear had better sensitivity but worse
specificity than the PHQ-9-algorithm. However, this finding
could result from choosing a PHQ-9-linear cut-off threshold
which is too low. Regarding the PHQ-2, it had significantly greater
specificity over the PHQ-9-linear method. Analysis using the ROC
meta-analysis suggested that the area under the ROC of the PHQ-
9-linear as well as that of the PHQ-2 was significantly higher than
the PHQ-9-algorithm which was surprising given that the PHQ-9-
algorithm more tightly adheres to the DSM criterion standard.
The difference was maintained when PHQ-9-linear and PHQ-9-
algorithm were compared with analysis was restricted to four
head-to-head studies. In head-to-head studies, the tools are tested
against one another in the same sample, ruling out differences
according to prevalence or local conditions. Using the same
methods, there was no clear differences between the PHQ-2 and
PHQ9-linear which again is surprising given the brevity of the
PHQ-2.
However, these results do not clarify a specific role for any
method in either screening or case finding. For case finding,
consistent with previous literature, all methods were disappointing
with the results on the CUI+ graded as ‘very poor’. Looking at
PPV alone for all methods using the Bayesian curve, results were
similarly poor thus confirming overall poor performance of this
method at typical prevalence rates seen in primary care. In short, a
positive test is infrequent in a typical primary care sample and/
or a positive test (when it does occur) is not especially discri‐
minating. For application as a screening test all methods were
encouraging with the following results on the CUI−: PHQ-9-
linear 0.827 (0.826–0.828), PHQ-9-algorithm 0.873 (0.873–0.873)
and PHQ-2 0.708 (0.707–0.709), all suggesting good to excellent
performance at typical prevalence rates. In NPV, values were all
high. Examining this effect in more detail using a Bayesian curve
of conditional probabilities demonstrated (Figs 3 and 4) that
although none of the methods performed particularly well at case
finding at any prevalence rate when used alone, they performed
reasonably well at initial first step. The most practical use of these
tools would be the PHQ-2 used as an initial screener followed by
either the PHQ-9-linear or another suitable case-finding tool.
We also analysed the effect of varying the cut-point. If simply
considering sensitivity and specificity, then the cut-point analysis
suggested that the current thresholds of ≥10 on the PHQ-9
and ≥2 on the PHQ-2 are very close to optimal. However, as
discussed above there is more to the application of tests in clinical
practice than simply looking at combined sensitivity and specifi-
city. Clinical utility is better represented by PPV and NPV. Using
PPV and NPV (combined) suggests that a substantially higher
cut-point in both the PHQ-9 and the PHQ-2 may be appropriate.
Furthermore, if one discounts their role in case finding and simply
concentrates on rule-out ability (CUI–), then the optimal cut
points would be ≥14 on the PHQ-9 and ≥6 on the PHQ-2.
Although these high thresholds are surprising, it is evident that
those without MDD, 98.6% have a score of 5 or lower on the
PHQ-2 and of those with a score of 5 or lower, 93.5% are true
negatives (true non-cases). Similarly, 96.5% of non-cases scored
<14 on the PHQ-9 and of those that do, 92.9% are true negatives.
We suggest further work is required to examine the optimal cut-
off thresholds if a two-step procedure were to be used.
Limitations
We acknowledge that there were relatively few studies with all the
required subgroups and not all studies reported ROC data (but we
were able to calculate this in many cases). To date, studies have
not attempted to clarify whether the sample comprises previously
untreated or previously undiagnosed patients. We did not attempt
to look at severity assessment or sensitivity to change. It must also
be acknowledged that the results presented represent the outcome
of a single application of the PHQ. Multiple (serial) applications
may be conducted in clinical practice and would change results.
For completeness, if the PHQ-2 is initially applied (step 1),
followed by PHQ-9-linear to those who score positive in step 1,
then the combined sensitivity would be 72.4% and specificity
96.4% (overall accuracy 93.0%). If the PHQ-2 were to be initially
applied followed by PHQ-9-algorithm, the combined sensitivity
would be 50.7% and specificity 98.4% (overall accuracy 91.6%).
Clinical implications and further research
The PHQ has potential to be used to rule out those without
depression with few false negatives but an adjustment of the cut-
off points (≥14 on the PHQ-9 and ≥6 on the PHQ-2) should be
considered. Alternatively its routine use can be improved by a
two-step procedure using PHQ-2 and then PHQ-9. This would
also reduce the burden on clinicians as the PHQ-9 would only be
applied following a positive initial PHQ-2 screen. Depression tools
applied for the purpose of screening and/or case finding will only
be of use if combined with adequate follow-up and adequate
treatment. Screening without removal of barriers to high-quality
care is potentially frustrating and arguably counterproductive.
Several reviews found modest evidence to support QoF-based
PHQ scoring in part because primary care clinicians may lack the
skills or resources to appropriately follow-up a positive screen.26,69
Further work on cut-off thresholds and repeat assessment may
further improve results but care must be taken not to increase the
burden on clinicians if they are required to implement screening
tools.
This meta-analysis confirms that neither the PHQ-9 nor the
PHQ-2 can confirm a diagnosis of MDD when used alone as a
one-off measure and this is independent of the scoring method.
However, the PHQ-9 and indeed the PHQ-2 can be used as an
initial first screening step and indeed performs quite well in this
regard.
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